Alvogen's generic version of Suboxone Film for opioid addiction did not infringe upon three patents held by Indivior PLC.
The United States District Court for the District of Delaware ruled that Alvogen's generic version of Suboxone Film did not infringe upon three patents ('514, '150, and '497) held by Indivior PLC.
As of March 22, the FDA has not given marketing authorization to Alvogen's copy of the opioid addiction treatment. Indvior warned in a statement that any launch of the generic alternative would be considered "at risk," allowing Indivior to sue for damages. The patent decision will likely negatively affect the business of Invidior as the film is responsible for a large portion of the company's revenue.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.